Ann K. Daly

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

Peter Kuehl, Jiong Zhang, Yvonne Lin et al. · Nature Genetics · 2001 · 2.2K citations

Life Sciences, Genetics, Molecular Biology +17

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol et al. · Nature · 2021 · 1.2K citations · Full text

Life Sciences, Immunology, Oncology +17

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

Guruprasad P. Aithal, Christopher P. Day, Patrick Kesteven et al. · The Lancet · 1999 · 1.2K citations

Medicine, Pharmacokinetics, Pharmacology +12

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin

Ann K. Daly, Peter T. Donaldson, Pallav Bhatnagar et al. · Nature Genetics · 2009 · 1K citations

Life Sciences, Genetics, Pharmacology +14

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

Elizabeth Sconce, Tayyaba Khan, Hilary Wynne et al. · Blood · 2005 · 947 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17